ScripMerck & Co’s PD-1 inhibitor for multiple cancer indications Keytruda (pembrolizumab) comfortably retained its number one spot as the drug generating the highest global revenues in the first quarte
ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
Pink SheetTop cell and gene therapy regulators Nicole Verdun and her deputy Rachael Anatol were forced out of the US Food and Drug Administration June 18, per multiple sources familiar with the matter. A commen
ScripPresident Donald Trump is repeating his threats of tariffs on the pharmaceutical industry and pressurizing companies to bring more manufacturing back to the US and while Ireland would be, on paper